nsclc

Showing 1 - 25 of 279

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

APOLLO 11, Consortium of Italian Centers Involved in Treatment

Not yet recruiting
  • NSCLC
  • +4 more
    • (no location specified)
    Sep 19, 2022

    Multicenter, Prospective, Real World Study of Camrelizumab in

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Sep 19, 2022

    Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

    Not yet recruiting
    • Phase 1
    • +9 more
    • Oral MRT-2359
    • Scottsdale, Arizona
    • +7 more
    Sep 16, 2022

    NSCLC Trial in Worldwide (Afatinib)

    Completed
    • NSCLC
    • Köln, Germany
    • +4 more
    Aug 23, 2022

    Nonsmall Cell Lung Cancer, NSCLC Trial in Worldwide (NovoTTF-200T, Immune checkpoint inhibitors or docetaxel)

    Active, not recruiting
    • Nonsmall Cell Lung Cancer
    • NSCLC
    • NovoTTF-200T
    • Immune checkpoint inhibitors or docetaxel
    • Birmingham, Alabama
    • +123 more
    Aug 18, 2022

    First Real-world Data on Unresectable Stage III NSCLC Patients

    Active, not recruiting
    • NSCLC
      • Ballarat, Australia
      • +253 more
      Aug 17, 2022

      NSCLC Trial in Chattanooga, Nashville (Aumolertinib, Osimertinib)

      Not yet recruiting
      • NSCLC
      • Chattanooga, Tennessee
      • +1 more
      Aug 16, 2022

      Cancer, Solid Tumor, Solid Carcinoma Trial in Houston (AMXT1501, DFMO)

      Recruiting
      • Cancer
      • +18 more
      • Houston, Texas
        MD Anderson Cancer Center
      Aug 12, 2022

      Outcomes of ALK-Positive Advanced NSCLC Participants Treated

      Recruiting
      • NSCLC
      • Ciudad Autonoma Buenos Aires, Argentina
      • +125 more
      Aug 12, 2022

      NSCLC Trial in Shanghai, Hangzhou (D-1553, Other)

      Not yet recruiting
      • NSCLC
      • Shanghai, Shanghai, China
      • +1 more
      Aug 11, 2022

      RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

      Recruiting
      • Nsclc
      • KRAS P.G12C
        • Paris, France
        • +2 more
        Aug 9, 2022

        SBRT, NSCLC, Non-metastatic Trial in United States (GC4711, Placebo)

        Recruiting
        • SBRT
        • +2 more
        • Gilbert, Arizona
        • +11 more
        Aug 9, 2022

        Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

        Recruiting
        • Non Small Cell Lung Cancer
        • +3 more
        • Core needle biopsy
        • Madison, Wisconsin
          Elephas
        Aug 4, 2022

        NSCLC, Other Solid Tumors Trial in Australia (GB263T)

        Recruiting
        • NSCLC
        • Other Solid Tumors
        • GB263T
        • Saint Leonards, New South Wales, Australia
        • +3 more
        Aug 3, 2022

        NSCLC Trial in Guangzhou (HA121-28 tablet)

        Recruiting
        • NSCLC
        • HA121-28 tablet
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Centre
        Aug 2, 2022

        Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

        Recruiting
        • Triple Negative Breast Cancer
        • +14 more
        • LYL797
        • New Haven, Connecticut
        • +6 more
        Jul 28, 2022

        Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)

        Recruiting
        • Ovarian Cancer
        • +3 more
        • Duarte, California
        • +4 more
        Jul 29, 2022

        Artificial Intelligence, Endobronchial Ultrasound, Elastography Trial in Hamilton (EBUS-Elastography)

        Completed
        • Artificial Intelligence
        • +4 more
        • EBUS-Elastography
        • Hamilton, Ontario, Canada
          St. Joseph's Healthcare Hamilton
        Jul 25, 2022

        Docetaxel Ethanol-induced Symptoms; The Incidence and Risk

        Completed
        • Breast Cancer
        • +6 more
          • Guri-si, Korea, Republic of
            Hanyang University Guri Hospital
          Jul 26, 2022

          Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)

          Recruiting
          • Advanced Malignancies
          • +4 more
          • Springdale, Arkansas
          • +20 more
          Jul 21, 2022

          Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)

          Recruiting
          • Non-Small-Cell Lung Cancer
          • NSCLC
          • Nagoya, Aichi, Japan
          • +2 more
          Jul 21, 2022

          NSCLC Trial (Furmonertinib)

          Not yet recruiting
          • NSCLC
          • (no location specified)
          Jul 17, 2022

          Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

          Recruiting
          • Furmonertinib
          • +3 more
          • Beijing, China
            Ethics Committee
          Jul 15, 2022

          Solid Tumor, NSCLC, Cervical Cancer Trial in China (Afuresertib, Nab paclitaxel, Docetaxel)

          Recruiting
          • Solid Tumor
          • +5 more
          • Beijing, Beijing, China
          • +4 more
          Jul 15, 2022

          NSCLC Trial (Lazertinib group)

          Not yet recruiting
          • NSCLC
          • Lazertinib group
          • (no location specified)
          Jul 14, 2022